An interventional study of Synapse platform in Drug-drug Interactions and Geriatric Disease, sponsored by University Hospital, Bordeaux. Terminated at 5 sites in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Health services research
Polypharmacy in the older adults is common and promotes the risk of drug interactions. The hypothesis evoked is that a virtual platform with artificial intelligence applied to the health, and in particular to the good use of the drug, could bring aids to the doctors them of the prescription of drugs. The main objective of this study is to evaluate the impact of geriatric use of the Synapse platform on the frequency of inappropriate medication prescriptions (STOPP criteria) in discharge orders for patients 65 years of age or older hospitalized in geriatric department.
The French 2018-2022 National Health Strategy plan aims to reduce the proportion of potentially harmful medication use. One particular challenge is the phenomenon of polypharmacy and inappropriate medication use in elderly, which is associated to an increased risk of drug-drug interactions. Several scales and tools have been proposed to identify inappropriate drugs prescription in older adults. Among them, the STOPP / START criteria (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment) are internationally recognized.
The Synapse platform offers a panel of functions that may help physicians to prescribe medications. For instance, the prescriber can interact with the Synapse platform by asking any type of question about a drug (dosage, contraindication, interaction ...) before prescription. It also allows them to take a picture of prescription. The software detects in less than 10 seconds criteria for inappropriate medication prescriptions and potential drug-drug interactions.
More precisely, the Synapse platform provides information on a particular drug or prescription analysis regarding:
Multiple new health technologies are emerging, but few of them have demonstrated their scientific and medical added value using an evidence-based medicine approach.
This clinical trial aims to validate the clinical interest of the Synapse application in a geriatric environment.
Prescriptions made by geriatricians participating in this study will be analyzed by two independent experts, including one pharmacist and one geriatrician.
University Hospital, Bordeaux is the lead sponsor of 783 studies on the registry; 188 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Male or female age aged more than 65 years
Adults protected by law
With prescription assistance device: During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline).
Device: Synapse platform
During 3 months, investigators will not have the Synapse platform and will make their prescriptions with the usual tools which they have: Modules of help in the DxCare® software of the CHU, public database of the drugs, dictionary Vidal®, …
The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions. The Synapse platform offers a panel of functions to help the doctor to prescribe medication.
Number of patients with decrease in STOPP criteria number between initial prescription and exist prescription.
Proportion of patients with decrease in STOPP criteria number between initial prescription and exist prescription.
Time frame: Month 6
Number of patients with increase in START criteria number between initial prescription and exist prescription.
Proportion of patients with increase in START criteria number between initial prescription and exist prescription.
Time frame: Day 1
Number of patients with increase in START criteria number between initial prescription and exist prescription.
Proportion of patients with increase in START criteria number between initial prescription and exist prescription.
Time frame: Month 6
Number of STOPP criteria
Difference in the number of STOPP criteria between initial and discharge prescription
Time frame: Day 1
Number of STOPP criteria
Difference in the number of STOPP criteria between initial and discharge prescription
Time frame: Month 6
Number of START criteria
Difference in the number of START criteria between initial and discharge prescription.
Time frame: Day 1
Number of START criteria
Difference in the number of START criteria between initial and discharge prescription.
Time frame: Month 6
number of patients with decrease in contraindicated drug-drug interaction
Proportion of patients with decrease in contraindicated drug-drug interaction number between initial and discharge prescription
Time frame: Day 1
number of patients with decrease in contraindicated drug-drug interaction
Proportion of patients with decrease in contraindicated drug-drug interaction number between initial and discharge prescription
Time frame: Month 6
Number of patients with decrease if active pharmaceutical ingredients
Proportion of patients with decrease in number of active pharmaceutical ingredients between initial and discharge prescription
Time frame: Day 1
Number of patients with decrease if active pharmaceutical ingredients
Proportion of patients with decrease in number of active pharmaceutical ingredients between initial and discharge prescription
Time frame: Month 6
Number of connections per week on Synapse platform by geriatricians
Number of connections per week on Synapse platform by geriatricians
Time frame: Month 6
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux